Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: a series of 15 cases and review of the literature

    ... did not have bone marrow transplantation or eculizumab therapy. Cases of death were mainly related to hepatic vein ...

    Research Article last updated 03/02/2015 - 11:38am.

  2. Paroxysmal nocturnal hemoglobinuria from bench to bedside

    ... GPI-anchor and serves as a novel reagent diagnosing PNH. Eculizumab , a humanized monoclonal antibody against C5, is the ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

    ... to additional complications, such as thrombosis. Eculizumab , a humanized monoclonal antibody against the C5 ...

    Research Article last updated 05/14/2013 - 3:28pm.

  4. Anastasios Karadimitris, MD, PhD

    ... anaemia and the propensity to developing blood clots. Eculizumab prevents the deleterious effects of complement, improves the ...

    Grant Recipient last updated 03/07/2017 - 9:50am.

  5. Keith McCrae, MD

    ... all but one of our PNH patients have been treated with eculizumab (Soliris®), which would be expected to prevent ... in normal individuals, and inhibition of this pathway by eculizumab actually reduces AP activation to a level below that in control ... this nature may be of use in dictating dosing intervals of eculizumab. Again, further analysis is warranted before conclusions can be ...

    Grant Recipient last updated 02/27/2017 - 7:05am.

  6. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... (PNH) who are still anemic after treatment with eculizumab (Soliris®). Status:  ... Diagnosed with PNH On treatment with eculizumab (Soliris®) for at least 3 months Hb < 10 g/dL at ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.

  7. AA&MDSIF announces PNH grant awards

    ... hemolytic anemia, risk for blood clots and early death. Eculizumab is an expensive FDA-approved drug to treat PNH but must be given intravenously. Up to 20% of PNH patients treated with eculizumab continue to need transfusions. The goal of this project is to ...

    Article last updated 12/14/2016 - 11:41am.

  8. Kimberly Woudenberg – Knowing What it Takes

    ... I had to face how this disease affected me. I started eculizumab (Soliris®) and my blood counts stabilized, but remained ...

    Patient Chronicle last updated 05/18/2015 - 2:57pm.

  9. A Story of Hope: Emma Pritchett

    ... regularly sees her local hematologist.  “Soliris ® ( eculizumab ) has been a life-changer,” she said.  “Things are so much ...

    Patient Chronicle last updated 05/18/2015 - 2:56pm.

  10. Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

    ...

    Research Article last updated 10/11/2011 - 5:58pm.